mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
14 Dec 2021
14 Dec 2021
Historique:
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that were vaccinated recently (<3 months), distantly (6-12 months), or recently boosted, and accounted for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinated individuals. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron only 4-6-fold lower than wild type, suggesting that boosters enhance the cross-reactivity of neutralizing antibody responses. In addition, we find Omicron pseudovirus is more infectious than any other variant tested. Overall, this study highlights the importance of boosters to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.
Identifiants
pubmed: 34931201
doi: 10.1101/2021.12.14.21267755
pmc: PMC8687472
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
J Virol. 2004 Oct;78(19):10628-35
pubmed: 15367630
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Lancet Microbe. 2021 Nov 15;:
pubmed: 34806056
Elife. 2021 Aug 20;10:
pubmed: 34414884
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
J Biomol Screen. 2013 Apr;18(4):453-61
pubmed: 23112084
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Lancet Microbe. 2021 Oct 26;:
pubmed: 34723229
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705
pubmed: 34882654
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
J Infect Dis. 2021 Dec 09;:
pubmed: 34888672
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Viruses. 2020 May 06;12(5):
pubmed: 32384820
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Biosaf Health. 2020 Dec;2(4):226-231
pubmed: 32864605